Evidence map›Paper›PMID 24195987›Full record

ArticleOphthalmic plastic and reconstructive surgery

Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas.

Tarek El-Sawy, Steven J Frank, Ehab Hanna, Matthew Sniegowski, Stephen Y Lai, Qasiem J Nasser, Jeffrey Myers, Bita Esmaeli

Open access · greenAbstract read
In one paragraph

Article in Ophthalmic plastic and reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Article
  3. Nasolacrimal Metastasis from Parotid Ductal Carcinoma Detected byMolecular imaging and radionuclide therapy · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Value ofDiagnostics (Basel, Switzerland) · 2021
    Article
  9. Rare transitional cell carcinoma of the lacrimal sac.American journal of ophthalmology case reports · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Lacrimal Sac Metastasis from Phyllodes Tumor of the Breast.Korean journal of ophthalmology : KJO · 2020
    Article
  14. Article
  15. Review
  16. Clinical analysis of 90 cases of malignant lacrimal sac tumor.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  17. Review
  18. Article
  19. Imaging Features of Malignant Lacrimal Sac and Nasolacrimal Duct Tumors.AJNR. American journal of neuroradiology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tarek El-Sawy*Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, †Department of Radiation Oncology, and ‡Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
Steven J Frank
Ehab Hanna
Matthew Sniegowski
Stephen Y Lai
Qasiem J Nasser
Jeffrey Myers
Bita Esmaeli
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeTo determine the rates of globe-sparing treatment and useful final visual function in patients with primary lacrimal sac/nasolacrimal duct carcinomas treated with multidisciplinary therapy.

methodsThe medical records of 14 patients with primary lacrimal sac/nasolacrimal duct carcinoma treated at 1 institution were retrospectively reviewed.

resultsThe patients were 9 men and 5 women; the median age at diagnosis was 58.5 years (range, 45-73 years). Seven patients presented with epiphora, 7 with a palpable mass in the inferomedial orbit, and 2 with dacryocystitis. In 3 patients, the diagnosis of cancer was not considered until during or after dacryocystorhinostomy. Seven patients had squamous cell carcinoma, 2 transitional cell carcinoma, 2 adenoid cystic carcinoma, and 1 each adenocarcinoma, poorly differentiated carcinoma, and inverted papilloma with carcinoma in situ transformation. Nine patients underwent surgical resection of the lacrimal sac and nasolacrimal duct and resection of the medial upper and lower eyelids, including canaliculi, partial ethmoidectomy, and medial maxillectomy. One patient underwent lacrimal sac biopsy only as another primary malignancy was discovered during the work-up for systemic disease. Four patients underwent orbital exenteration because of extensive involvement of the orbital soft tissue. Radiotherapy was recommended for 13 patients; in 1 patient, radiotherapy was not recommended because the patient had an inverted papilloma with carcinoma in situ transformation that was completely excised. The median radiation dose was 60 Gy. Eight patients received chemotherapy either concurrent with radiation therapy (5 patients), as neoadjuvant treatment (1 patient), or for progressive or metastatic disease (3 patients). The median follow-up time was 27 months (range, 6-96 months). In 10 patients, the globe was spared. In 9 of these 10 patients, visual acuity was the same as at baseline or better than 20/40 at last follow up.

conclusionsWith multidisciplinary therapy, the eye can be spared and reasonable visual function can be preserved in most patients with primary lacrimal sac/nasolacrimal duct carcinomas.

Indexed as

AgedCarcinomaCombined Modality TherapyEye NeoplasmsFemaleFollow-Up StudiesHumansLacrimal Apparatus DiseasesMaleMiddle AgedNasolacrimal DuctNose NeoplasmsOrbit EviscerationRadiation DosageRetrospective StudiesVisual Acuity

Identifiers

PMID24195987
PMCPMC3830646
OpenAlexW2087858890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.